FOX BIZ NEWS: FDA panel reviews 1st new Alzheimer’s drug in 2 decades


FDA panel reviews 1st new Alzheimer’s drug in 2 decades



A panel of outside experts meets Friday to advise the Food and Drug Administration on aducanumab, a drug from Cambridge, Massachusetts-based Biogen Inc. and Japan’s Eisai Co. FDA doesn’t always follow the panel’s advice but usually does and has until March to decide.

Comments

Popular posts from this blog

Covid live: Record 50,000+ infections on Sunday

Impact of pandemic? Women jobseekers fell by 34% in 2021

SC slams trial courts for seeking needless custody